Aeterna Zentaris Inc. (NASDAQ:AEZS – Get Rating) (TSE:AEZ) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 87,000 shares, an increase of 7.0% from the February 13th total of 81,300 shares. Based on an average daily trading volume, of 15,700 shares, the short-interest ratio is presently 5.5 days. Currently, 1.8% of the company’s shares are sold short.
Aeterna Zentaris Price Performance
Shares of NASDAQ AEZS opened at $2.67 on Thursday. The company has a 50 day simple moving average of $3.50 and a 200 day simple moving average of $3.73. The firm has a market cap of $12.98 million, a PE ratio of -1.04 and a beta of 1.43. Aeterna Zentaris has a 1 year low of $2.54 and a 1 year high of $9.75.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on shares of Aeterna Zentaris in a report on Saturday, March 11th. They set a “sell” rating for the company.
About Aeterna Zentaris
Æterna Zentaris, Inc operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.
- Get a free copy of the StockNews.com research report on Aeterna Zentaris (AEZS)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.